Intratect

Human normal immunoglobulin, the active ingredient in Intratect, is a Immunoglobulin (IVIG) presented as a solution for injection for intravenous use. It replaces deficient immunoglobulins and modulates immune responses in patients with primary or secondary immunodeficiency, immune thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution across multiple regions.

Intratect is used to treat disorders of the immune system by providing pooled IgG antibodies.

Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency. Secondary immunodeficiency: supplies missing antibodies in patients with secondary immune deficiency. Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑immune platelet destruction. Kawasaki disease: reduces coronary artery inflammation in acute phase. Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability by dampening autoimmune nerve damage.

Intratect may be associated with a range of infusion‑related and systemic adverse reactions.

Common Side Effects: - Headache - Fever or chills - Nausea or vomiting - Fatigue - Mild infusion site reactions (redness, swelling)

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Thromboembolic events (stroke, myocardial infarction, deep vein thrombosis) - Acute renal dysfunction or failure - Aseptic meningitis - Hemolytic anemia - Severe hypotension or cardiovascular collapse

Before initiating Intratect therapy, clinicians should consider several precautionary measures to ensure patient safety. - Assess baseline IgG levels: determine need for replacement therapy. - Screen for renal impairment: monitor creatinine and adjust infusion rate if needed. - Evaluate thrombotic risk: avoid rapid infusion in patients with history of clotting disorders. - Test for anti‑IgA antibodies: patients with IgA deficiency may develop severe reactions. - Review concomitant medications: anticoagulants and high‑dose aspirin may increase bleeding risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other agents, influencing efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: immunoglobulin may neutralize vaccine efficacy. - High‑dose aspirin or other NSAIDs: increase risk of bleeding when combined with IVIG. - Concurrent administration of other immunoglobulin products: may cause additive volume overload.

Moderate Interactions (Monitor Closely): - Corticosteroids: may augment immunosuppressive effect, monitor infection signs. - Rituximab or other B‑cell depleting agents: schedule IVIG at least 2 weeks apart to avoid reduced efficacy. - Anticoagulants (warfarin, DOACs): monitor coagulation parameters as IVIG can affect INR.